All In Biotech

BLA 761099 · Pfizer INC

Zirabev

Bevacizumab-Bvzr · Injection · Vascular Endothelial Growth Factor Inhibitor

Last checked: Nov 20, 2026Latest source record: Aug 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Jun 27, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

2,998

508 Phase 3, 455 recruiting

FAERS reports

705

568 serious, 207 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 21, 2026.

ZIRABEV is a vascular endothelial growth factor inhibitor indicated for the treatment of: • Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) • Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : ZIRABEV is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) • Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) • Recurrent glioblastoma in adults. ( 1.3 ) • Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) • Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan. ( 1.5 ) • Epithelial ovarian, fallopian tube, or primary peritoneal cancer: o in combination with carboplatin and paclitaxel, followed by ZIRABEV as a single agent, for stage III or IV disease following initial surgical resection. ( 1.6 ) o in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) o in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by ZIRABEV as a single agent, for platinum-sensitive recurrent disease. ( 1.6 ) 1.1 Metastatic Colorectal Cancer ZIRABEV, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first- or second-line treatment of patients with metastatic...

Mechanism: Bevacizumab products bind VEGF and prevent the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 9, 2021 Supplement 4 · Efficacy LetterLabel
  • Jun 27, 2019 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
2 products under this application
  • ZIRABEV · BEVACIZUMAB-BVZR 400MG/16ML · INJECTABLE, INJECTION · Prescription
  • ZIRABEV · BEVACIZUMAB-BVZR 100MG/4ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bevacizumab" as an intervention, any sponsor and status, largest first.

All 2,998 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use171
  • death162
  • neoplasm progression82
  • fatigue68
  • weight decreased47
  • hypertension46
  • blood pressure increased44
  • weight increased37
  • inappropriate schedule of product administration32
  • malaise32
  • asthenia30
  • nausea30

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202039
202191
2022159
2023164
2024148
202566
202638

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zirabev (Bevacizumab-Bvzr)

2024 spending

$9.6M

Beneficiaries

393

1,848 claims

Per beneficiary

$24,385

$146.68 per unit

View as table
YearSpending
2020$632,798
2021$2,738,155
2022$7,020,883
2023$8,660,407
2024$9,583,179

Part B: Zirabev (Bevacizumab-Bvzr) · HCPCS Q5118

2024 spending

$75.8M

Beneficiaries

8,712

50,618 claims

Per beneficiary

$8,702

2024 ASP limit $21.71 per unit

View as table
YearSpending
2020$33,154,601
2021$172,471,886
2022$240,472,911
2023$157,233,199
2024$75,813,627

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,932 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.